Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 01, 2025 13:00 ET | Source: DelveInsight Business Research LLP

Geographic Atrophy Market to Surge Significantly During the Forecast Period (2025–2034) Due to Rising Adoption of Complement Inhibitor Therapies | DelveInsight

New York, USA, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Geographic Atrophy Market to Surge Significantly During the Forecast Period (2025–2034) Due to Rising Adoption of Complement Inhibitor Therapies |...
May 07, 2025 08:59 ET | Source: Alkeus Pharmaceuticals

Alkeus Pharmaceuticals Presents Gildeuretinol Data During the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting May 4-8, 2025

Alkeus Pharmaceuticals presents gildeuretinol data during the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting May 4-8, 2025
April 24, 2025 10:59 ET | Source: Alkeus Pharmaceuticals

Alkeus Pharmaceuticals Announces Presentations of Gildeuretinol Data During the Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting May 4-8, 2025

Alkeus Pharmaceuticals announces presentations of gildeuretinol data in Stargardt and GA during ARVO May 4-8
February 11, 2025 08:30 ET | Source: Alkeus Pharmaceuticals

Alkeus Pharmaceuticals Announces Two Presentations of Oral Gildeuretinol Data During the 48th Annual Meeting of the Macula Society Being Held February 12-15, 2025

CAMBRIDGE, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today...
October 23, 2024 09:00 ET | Source: Alkeus Pharmaceuticals

Topline Results from Alkeus Pharmaceuticals’ Study of Oral Gildeuretinol Demonstrate Significant Trend in Slowing GA Progression and Visual Function Improvement

Alkeus Pharmaceuticals, Inc., today announced that results from its study of gildeuretinol in geographic atrophy were presented at AAO 2024.
October 17, 2024 08:29 ET | Source: Alkeus Pharmaceuticals

Alkeus Pharmaceuticals Announces Data Presentations at the American Academy of Ophthalmology (AAO) 2024 Annual Meeting, October 18-21 in Chicago

Results from Study of Oral Gildeuretinol for Geographic Atrophy Secondary to Age-Related Macular Degeneration to be Presented as Late-Breaker During Retina Subspecialty Day Positive Data from TEASE...
September 20, 2024 09:53 ET | Source: SNS Insider pvt ltd

Geographic Atrophy (GA) Market Size to Hit USD 50.0 Billion by 2032 with a 8.6% CAGR – SNS Insider

Pune, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Geographic Atrophy (GA) Market Size & Growth Analysis: According to SNS Insider, The Geographic Atrophy Market was valued at USD 23.7 billion in 2023...
September 05, 2024 10:52 ET | Source: Boehringer Ingelheim

Boehringer Ingelheim announces plans to advance potential new treatment for Geographic Atrophy, following positive Phase I results

Ingelheim, Germany and Basel, Switzerland, September 5, 2024 – Boehringer Ingelheim and CDR-Life today announce positive results from the Phase I evaluation of BI 771716 (Study Record |...
June 27, 2024 08:49 ET | Source: Spherix Global Insights

Treating Geographic Atrophy Remains a Tough Call for Ophthalmologists as They Voice Hesitancy to Prescribe Complement Inhibitors

Exton, Pennsylvania, June 27, 2024 (GLOBE NEWSWIRE) -- Prior to 2023, there was no treatment for GA, a progressive form of dry age-related macular degeneration that results in blindness. That...
May 01, 2024 14:17 ET | Source: Spherix Global Insights

Gene Therapies in Degenerative Retinal Disease Hold Potential to Capture Significant Portion of Market

EXTON, PA, May 01, 2024 (GLOBE NEWSWIRE) -- In the landscape of healthcare innovation, retinal disorders, including both inherited and degenerative diseases, have become a leading focus area for...